0
     

Report Added
Report already added
Pulmonary Arterial Hypertension (PAH) Market - Global Outlook and Forecast 2022-2028

Pulmonary Arterial Hypertension (PAH) Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Pulmonary Arterial Hypertension (PAH) in Global, including the following market information:

Global Pulmonary Arterial Hypertension (PAH) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Pulmonary Arterial Hypertension (PAH) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Prostacyclin and Prostacyclin Analogs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Arterial Hypertension (PAH) include Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer and Arena, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Arterial Hypertension (PAH) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Pulmonary Arterial Hypertension (PAH) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Pulmonary Arterial Hypertension (PAH) Market Segment Percentages, by Type, 2021 (%)
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Global Pulmonary Arterial Hypertension (PAH) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Pulmonary Arterial Hypertension (PAH) Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Pulmonary Arterial Hypertension (PAH) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Pulmonary Arterial Hypertension (PAH) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Arterial Hypertension (PAH) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Pulmonary Arterial Hypertension (PAH) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Pulmonary Arterial Hypertension (PAH) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Arterial Hypertension (PAH) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Arterial Hypertension (PAH) Overall Market Size
2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size: 2021 VS 2028
2.2 Global Pulmonary Arterial Hypertension (PAH) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Pulmonary Arterial Hypertension (PAH) Players in Global Market
3.2 Top Global Pulmonary Arterial Hypertension (PAH) Companies Ranked by Revenue
3.3 Global Pulmonary Arterial Hypertension (PAH) Revenue by Companies
3.4 Top 3 and Top 5 Pulmonary Arterial Hypertension (PAH) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Pulmonary Arterial Hypertension (PAH) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Players in Global Market
3.6.1 List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Companies
3.6.2 List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Pulmonary Arterial Hypertension (PAH) Market Size Markets, 2021 & 2028
4.1.2 Prostacyclin and Prostacyclin Analogs
4.1.3 SGC Stimulators
4.1.4 ERA
4.1.5 PDE-5
4.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Revenue & Forecasts
4.2.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2022
4.2.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2023-2028
4.2.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Revenue & Forecasts
5.2.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2022
5.2.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2023-2028
5.2.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Market Size, 2021 & 2028
6.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue & Forecasts
6.2.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2022
6.2.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue, 2023-2028
6.2.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028
6.3.2 US Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.3.3 Canada Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.3.4 Mexico Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028
6.4.2 Germany Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.3 France Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.4 U.K. Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.5 Italy Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.6 Russia Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.7 Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.4.8 Benelux Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028
6.5.2 China Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.5.3 Japan Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.5.4 South Korea Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.5.5 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.5.6 India Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028
6.6.2 Brazil Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.6.3 Argentina Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028
6.7.2 Turkey Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.7.3 Israel Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.7.4 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
6.7.5 UAE Pulmonary Arterial Hypertension (PAH) Market Size, 2017-2028
7 Players Profiles
7.1 Actelion
7.1.1 Actelion Corporate Summary
7.1.2 Actelion Business Overview
7.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.1.4 Actelion Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.1.5 Actelion Key News
7.2 Gilead Sciences
7.2.1 Gilead Sciences Corporate Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.2.5 Gilead Sciences Key News
7.3 United Therapeutics
7.3.1 United Therapeutics Corporate Summary
7.3.2 United Therapeutics Business Overview
7.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.3.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.3.5 United Therapeutics Key News
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Corporate Summary
7.4.2 GlaxoSmithKline Business Overview
7.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.4.4 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.4.5 GlaxoSmithKline Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.5.4 Pfizer Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.5.5 Pfizer Key News
7.6 Bayer
7.6.1 Bayer Corporate Summary
7.6.2 Bayer Business Overview
7.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.6.4 Bayer Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.6.5 Bayer Key News
7.7 Arena
7.7.1 Arena Corporate Summary
7.7.2 Arena Business Overview
7.7.3 Arena Pulmonary Arterial Hypertension (PAH) Major Product Offerings
7.7.4 Arena Pulmonary Arterial Hypertension (PAH) Revenue in Global Market (2017-2022)
7.7.5 Arena Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Pulmonary Arterial Hypertension (PAH) Market Opportunities & Trends in Global Market
Table 2. Pulmonary Arterial Hypertension (PAH) Market Drivers in Global Market
Table 3. Pulmonary Arterial Hypertension (PAH) Market Restraints in Global Market
Table 4. Key Players of Pulmonary Arterial Hypertension (PAH) in Global Market
Table 5. Top Pulmonary Arterial Hypertension (PAH) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Pulmonary Arterial Hypertension (PAH) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Pulmonary Arterial Hypertension (PAH) Product Type
Table 9. List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Pulmonary Arterial Hypertension (PAH) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Pulmonary Arterial Hypertension (PAH) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Pulmonary Arterial Hypertension (PAH) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Pulmonary Arterial Hypertension (PAH) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2023-2028
Table 30. Actelion Corporate Summary
Table 31. Actelion Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 32. Actelion Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 33. Gilead Sciences Corporate Summary
Table 34. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 35. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 36. United Therapeutics Corporate Summary
Table 37. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 38. United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 39. GlaxoSmithKline Corporate Summary
Table 40. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 41. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 44. Pfizer Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 45. Bayer Corporate Summary
Table 46. Bayer Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 47. Bayer Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)
Table 48. Arena Corporate Summary
Table 49. Arena Pulmonary Arterial Hypertension (PAH) Product Offerings
Table 50. Arena Pulmonary Arterial Hypertension (PAH) Revenue (US$, Mn), (2017-2022)

List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Segment by Type in 2021
Figure 2. Pulmonary Arterial Hypertension (PAH) Segment by Application in 2021
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Pulmonary Arterial Hypertension (PAH) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
Figure 8. By Type - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 12. US Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 16. Germany Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 17. France Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 24. China Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 28. India Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 30. Brazil Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Revenue Market Share, 2017-2028
Figure 33. Turkey Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Pulmonary Arterial Hypertension (PAH) Revenue, (US$, Mn), 2017-2028
Figure 37. Actelion Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. United Therapeutics Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bayer Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Arena Pulmonary Arterial Hypertension (PAH) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Report Title: Pulmonary Arterial Hypertension (PAH) Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW